"These are the first clinical data from our Phase 1b ALPINE study to be presented in a scientific forum and we are pleased that the combination of OMP-59R5 with standard-of-care gemcitabine and Abraxane has been well tolerated," said Jakob Dupont, M.D., OncoMed's Chief Medical Officer. "Additionally, the early signs of potential efficacy in patients with metastatic pancreatic cancer are encouraging and we anticipate advancing OMP-59R5 into the randomized Phase 2 portion of the ALPINE study in the second quarter of 2014."Data from the ongoing Phase 1b ALPINE study were presented in a poster titled: Phase 1b of anti-cancer stem cell antibody OMP-59R5 (anti-Notch2/3) in combination with nab-Paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC) (Abstract #220; Poster Board A49). Paul J. Hastings, Chairman and Chief Executive Officer of OncoMed, commented, "We are pleased with the steady progress being made across our clinical-stage portfolio, including the efficient advancement of our OMP-59R5 program in pancreatic and small-cell lung cancer. With more than a dozen studies across five distinct anti-cancer stem cell therapeutics actively enrolling patients, we can look forward to reporting additional data and advancing multiple anti-CSC products into new clinical studies in the months to come." About OMP-59R5 OMP-59R5 is a fully human monoclonal antibody that targets the Notch2 and Notch3 receptors. Initially discovered by screening a phage display library against the Notch2 receptor, the antibody binds to a conserved epitope on Notch2 and Notch3. Preclinical studies have suggested that OMP-59R5 exhibits two mechanisms of action: (1) by downregulating Notch pathway signaling, OMP-59R5 appears to have anti-CSC effects, and (2) OMP-59R5 affects pericytes, impacting stromal and tumor microenvironment. The program is currently in two Phase 1b/2 proof-of-concept trials: 1) the " ALPINE" trial ( Antibody therapy in first- Line Pancreatic cancer Investigating anti- Notch Efficacy and safety) is testing OMP-59R5 with gemcitabine and Abraxane ® in first-line advanced pancreatic cancer patients; and 2) the " PINNACLE" trial ( Phase 1b/2 INvestigation of anti- Notch Antibody therapy with Cisplatin and etoposide in small cell Lung carcinoma Efficacy and safety), is testing OMP-59R5 in combination with cisplatin and etoposide in first-line extensive stage SCLC patients. OMP-59R5 is part of OncoMed's collaboration with GlaxoSmithKline (GSK). Data from the Phase 1b portion of the ALPINE study were presented in January 2014 at the Gastrointestinal Cancers Symposium held in San Francisco, CA. GSK has an option to obtain an exclusive license to OMP-59R5 during certain time periods through completion of the proof-of-concept Phase 2 trials. About Cancer Stem Cells Cancer stem cells, or CSCs, are the subpopulation of cells in a tumor responsible for driving growth and metastasis of the tumor. CSCs, also known as tumor-initiating cells, exhibit certain properties which include the capacity to divide and give rise to new CSCs via a process called self-renewal and the capacity to differentiate or change into the other cells that form the bulk of the tumor. Common cancer drugs target bulk tumor cells but have limited impact on CSCs, thereby providing a path for recurrence of the tumor. OncoMed's product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, and also impact bulk tumor cells. OncoMed believes its product candidates are distinct from the current generations of chemotherapies and targeted therapies, and have the potential to significantly impact cancer treatment and the clinical outcome of patients with cancer.